Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1865191 | 1.00 | TP53 (0.40) | TP53SLC7A5 | |
| SCHEMBL11996286 | 1.00 | TP53 (0.40) | TP53SLC7A5 | |
| Hydrochloric Acid SCHEMBL28540309 | 0.97 | TP53 (0.38) | TP53SLC7A5 | |
| SCHEMBL22692567 | 0.88 | TP53 (0.44) | TP53SLC7A5 | |
| SCHEMBL718215 | 0.88 | TP53 (0.44) | TP53SLC7A5 | |
| Sulfuric Acid SCHEMBL28413874 | 0.78 | TP53 (0.38) | TP53 | |
| SCHEMBL13033877 | 0.77 | TSHR (0.35) | — | |
| SCHEMBL25847798 | 0.76 | TDP1 (0.30) | — | |
| SCHEMBL22692558 | 0.76 | RNPEP (0.36) | TP53 | |
| SCHEMBL50988 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416111-B2 | Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150166486-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-18 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011051673-A1 | AMINOTHIAZOLE DERIVATIVES USEFUL AS KLK1 INHIBITORS | VANTIA LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051672-A1 | AZAINDOLE DERIVATIVES | VANTIA LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, PGC | TP53 4221/4885SLC7A5 3549/4885 |
| US-20150166486-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS | SYK, ZAP70, TYRO3 | TP53 717/4885SLC7A5 2447/4885 |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | TP53 489/4885SLC7A5 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.